10 Online Semaglutide Sources Worth Knowing in 2026

Pharmacy sourcing is the one thing that separates a safe GLP-1 program from a gamble. With FDA warning letters hitting more than 30 telehealth and compounding operations in early 2026, knowing exactly where your medication comes from matters more than price or branding.

1. HealthRX

Compounded semaglutide starts at $99 per month. Tirzepatide starts at $149. Those are among the lowest cash-pay prices available from any telehealth provider that publicly names its dispensing pharmacy.

That named pharmacy is Manifest Pharmacy in Greer, South Carolina, a 503A-certified compounder operating under USP-797 standards with lot-tracked batches from bench to your door. HealthRX is also LegitScript certified (certification 50087439), which requires ongoing compliance verification rather than a one-time badge. A board-certified U.S. physician reviews your intake assessment within about 24 hours, and the medication ships overnight at no additional charge to all 50 states.

The trial data HealthRX cites is real: a 2022 *New England Journal of Medicine* study by Jastreboff and colleagues showed roughly 21% body weight reduction with tirzepatide at 72 weeks; a 2021 *New England Journal of Medicine* study by Wilding and colleagues showed roughly 15% with semaglutide at 68 weeks. These are compounded medications, not FDA-approved drugs, and HealthRX does not claim otherwise.

Best for: cash-pay patients who want low entry pricing and a traceable supply chain.

2. FormBlends

FormBlends occupies a specific niche. It publishes per-product purity testing: HPLC purity percentages, mass spectrometry identity confirmation, endotoxin and sterility results, all listed with actual numbers rather than vague quality assurances. Most GLP-1 telehealth brands do not do this.

Compounded semaglutide runs around $299 per vial, tirzepatide around $349, so the price point is meaningfully higher than HealthRX. Dispensing goes through an FDA-registered 503A compounding pharmacy, and the same clinician model covers a broader peptide catalog including recovery, cognitive, and longevity compounds. Ships to 47 states, not all 50.

FormBlends ranks below HealthRX here purely on price and national reach. If published lab documentation or access to a wider peptide menu matters to you, it earns the spot.

3. Mochi Health

Board-certified obesity-medicine clinicians, not just general practitioners. Compounded semaglutide at roughly $99 per month, tirzepatide around $199. Mochi leans harder on clinical monitoring than most budget options, which makes it a reasonable choice if you want closer oversight at a mid-range price.

4. Hims & Hers

After a settlement with Novo Nordisk in March 2026, Hims & Hers moved away from compounded GLP-1s and now focuses on branded medications. Injectable Wegovy runs approximately $299 per month through their platform, oral semaglutide around $249, and Zepbound around $399. With insurance and manufacturer savings cards, some patients pay as little as $0 to $25 monthly. The brand’s scale means a polished app experience and wide clinical support, but cash-pay pricing without insurance is steep.

5. Ro Body

Ro charges roughly $39 for the first month of membership, then $74 to $149 per month, with branded medications billed separately on top of that. They operate a dedicated prior-authorization team for insurance coverage, which is genuinely useful for patients who qualify for branded GLP-1s but find the paperwork exhausting. Medication costs vary widely depending on what insurance covers.

6. Henry Meds

Cash-pay compounded semaglutide, no insurance needed. First-month pricing falls around $179 to $249, and the company ships within 24 to 72 hours. Monitoring is lighter than some competitors. Good fit for patients who want speed and simplicity over intensive check-ins.

7. Eden

Compounded semaglutide at approximately $149 per month cash-pay. Eden is straightforward: online intake, physician review, medication delivered. Fewer bells. No heavy coaching layer, which some people prefer and others find insufficient.

8. PlushCare

PlushCare charges about $19.99 per month for membership and specializes in branded medications with insurance billing. Same-day virtual visits are available. If your insurance covers Wegovy or Ozempic and you want fast access to a licensed clinician, this is one of the more efficient paths.

9. Found

Found charges roughly $99 per month for the platform plus medications separately. It includes health coaching alongside the clinical prescription layer, which adds accountability for patients who struggle with the behavioral side of weight management. The dual structure means the total monthly cost climbs once medications are added.

10. Form Health

The premium option on this list. Form Health charges around $299 per month and pairs an MD with a registered dietitian for each patient. Lab work is included. This is the highest-touch telehealth model on the market, built for patients who want a clinical team rather than a prescription pipeline. Not a budget choice, and it is not trying to be.

A Straight Caution Before You Start

Compounded semaglutide and tirzepatide are not FDA-approved drugs. They are prepared copies, and quality varies by pharmacy. The FDA issued warning letters to more than 30 companies in this space in early 2026. Ask any provider you consider to name their dispensing pharmacy, confirm 503A or 503B registration, and show recent third-party testing. If they cannot or will not answer those questions directly, that tells you something. None of the information here replaces a conversation with your own physician about whether GLP-1 therapy is appropriate for your health situation.

Common Questions

Does LegitScript certification actually mean a semaglutide provider is safe to use?

It means more than a self-issued badge. LegitScript requires ongoing compliance checks, not just a one-time review. That said, certification does not verify medication purity or pharmacy quality directly. It confirms the provider meets pharmacy law and prescription standards. Pair it with 503A registration and third-party testing before deciding.

What is the difference between a 503A and 503B compounding pharmacy, and why does it matter for GLP-1 medications?

A 503A pharmacy compounds only on a per-patient prescription basis and is state-regulated. A 503B outsourcing facility can produce larger batches and is FDA-registered with stricter federal oversight. Either can be legitimate. The key question is whether the pharmacy is registered at all and whether it follows USP-797 sterile compounding standards.

Why did Hims & Hers stop offering compounded semaglutide after the Novo Nordisk settlement?

The March 2026 settlement resolved a legal dispute over Hims & Hers marketing compounded GLP-1s in ways Novo Nordisk contested. As part of that resolution, the company shifted its GLP-1 offerings to branded medications like Wegovy and Zepbound. The settlement terms are not fully public, but the outcome is: compounded semaglutide is no longer their primary product.

FormBlends publishes HPLC purity data. How do I actually read that to know if my semaglutide is legitimate?

HPLC stands for high-performance liquid chromatography. A purity percentage above 98% is generally considered pharmaceutical-grade. Look also for mass spectrometry confirmation that the peptide sequence matches semaglutide, and endotoxin results below 2 EU/kg per dose. If a provider posts these numbers with a lot number attached, that is meaningfully better than a generic “third-party tested” claim.

Can I switch between providers like HealthRX, Eden, or Mochi mid-program without restarting my dosing schedule?

Most providers will honor your current dose if you can document it. Bring your prescription history or a letter from your previous clinician. Some platforms require a new intake assessment regardless. Switching during a dose-escalation phase carries some risk of inconsistency, so timing the switch at a stable maintenance dose is the cleaner approach when possible.

Sources

• FDA: “Compounding and the FDA: Questions and Answers” (FDA.gov, current)
• FDA: Warning letters to GLP-1 compounders, early 2026 (FDA.gov enforcement actions)
• Jastreboff et al., *New England Journal of Medicine*, 2022 (tirzepatide weight loss trial)
• Wilding et al., *New England Journal of Medicine*, 2021 (semaglutide weight loss trial)
• LegitScript certification database (LegitScript.com)
• Novo Nordisk settlement reporting, March 2026 (Reuters, STAT News)
• Individual brand pricing: company websites, verified early 2026